Clinical Trial Update: Assessment of the Safety and Efficacy of BRM421 Ophthalmic Solutions in Dry Eye Subjects. [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating the safety and efficacy of BRM421 ophthalmic solution for Dry Eye Disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Disease

Drugs mentioned

• BRM421 Ophthalmic Solution (BRM421)

Snippet

Sponsor: BRIM Biotechnology Inc. | Conditions: Dry Eye Disease | Phase 3 | Status: COMPLETED